GENCURIX
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test 2023-10-12 06:00
Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test 2023-06-14 09:00
Gencurix Announces Clinical Research Results At ASCO Demonstrating Outstanding Performance of GenesWellBCT Compared to Global Best-Selling Test, OncotypeDX 2023-06-07 12:29
Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX 2023-06-05 14:37
Gencurix announced Korean and Japanese cancer patients' 15-year follow-up prognostic test clinical results 2023-05-10 08:00
Gencurix wins FDA EUA for COVID-19 Test Kit 2020-06-24 21:00
Gencurix Releasing New Coronavirus Diagnostic Kit in the EU 2020-03-20 16:23
Gencurix's Study Explores the Difference between GenesWell BCT and Oncotype DX 2019-08-23 08:00
Gencurix Announces the First Comparison Data between GenesWell BCT and Oncotype DX 2019-08-14 09:00
New Publication Shows Different Result of Risk Classification between GenesWell BCT and Oncotype DX in Breast Cancer Patients 50 Years Old or Younger. 2019-08-12 21:00
1